Trellus Health plc

AIM:TRLS Stock Report

Market Cap: UK£928.7k

Trellus Health Management

Management criteria checks 1/4

Trellus Health's CEO is Marla Dubinsky, appointed in Jul 2022, has a tenure of 2.42 years. directly owns 5.42% of the company’s shares, worth £50.32K. The average tenure of the management team and the board of directors is 2.7 years and 2.5 years respectively.

Key information

Marla Dubinsky

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2.4yrs
CEO ownership5.4%
Management average tenure2.7yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

Is Trellus Health (LON:TRLS) In A Good Position To Invest In Growth?

Oct 05
Is Trellus Health (LON:TRLS) In A Good Position To Invest In Growth?

We're Not Very Worried About Trellus Health's (LON:TRLS) Cash Burn Rate

Jun 02
We're Not Very Worried About Trellus Health's (LON:TRLS) Cash Burn Rate

Companies Like Trellus Health (LON:TRLS) Are In A Position To Invest In Growth

Sep 12
Companies Like Trellus Health (LON:TRLS) Are In A Position To Invest In Growth

CEO Compensation Analysis

How has Marla Dubinsky's remuneration changed compared to Trellus Health's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$7m

Dec 31 2023n/an/a

-US$6m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

-US$8m

Mar 31 2023n/an/a

-US$8m

Dec 31 2022US$147kUS$147k

-US$9m

Sep 30 2022n/an/a

-US$9m

Jun 30 2022n/an/a

-US$9m

Mar 31 2022n/an/a

-US$8m

Dec 31 2021US$120kn/a

-US$6m

Compensation vs Market: Insufficient data to establish whether Marla's total compensation is reasonable compared to companies of similar size in the UK market.

Compensation vs Earnings: Marla's compensation has increased whilst the company is unprofitable.

CEO

Marla Dubinsky

2.4yrs

Tenure

US$146,542

Compensation

Dr. Marla Cindy Dubinsky, M.D. serves as Member of Scientific Advisory Board at Geneoscopy, Inc. since January 17, 2024. She serves as Chief, Division of Pediatric Gastroenterology at Mount Sinai Kravis Ch...

Leadership Team

NamePositionTenureCompensationOwnership
Marla Dubinsky
Co-Founder2.4yrsUS$146.54k5.42%
£ 50.3k
Laurie Keefer
Co-Founder & Chair of Scientific Advisory Boardno datano data5.42%
£ 50.4k
Joy Bessenger
Chief Financial Officer1.3yrsno datano data
Jamey Hancock
Chief Technology Officerno datano datano data
Amy Murphy
Director of Human Resourcesno datano datano data
Andres Jimenez
Chief Medical Information Officer3.3yrsno datano data
Leah Conley
Head of Global Market Access - Travere Therapeutics & Member of Scientific Advisory Board2.9yrsno datano data

2.7yrs

Average Tenure

Experienced Management: TRLS's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Marla Dubinsky
Co-Founder4.4yrsUS$146.54k5.42%
£ 50.3k
Laurie Keefer
Co-Founder & Chair of Scientific Advisory Boardno datano data5.42%
£ 50.4k
Leah Conley
Head of Global Market Access - Travere Therapeutics & Member of Scientific Advisory Board2.5yrsno datano data
Brian Griffin
Non-Executive Directorless than a yearno datano data
Traci Entel
Non-Executive Director2.5yrsUS$15.16kno data
David T. Rubin
Member of Scientific Advisory Boardno datano datano data
Kevin Murphy
Independent Non-Executive Chairmanless than a yearno datano data
Asher Kornbluth
Member of Scientific Advisory Boardno datano datano data
Charlie Lees
Member of Scientific Advisory Boardno datano datano data
Jessica Caron
Member of Scientific Advisory Boardno datano datano data
Leona Brandwene
Member of Scientific Advisory Boardno datano datano data
Corey Siegel
Member of Scientific Advisory Boardno datano datano data

2.5yrs

Average Tenure

Experienced Board: TRLS's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 17:36
End of Day Share Price 2024/12/19 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Trellus Health plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution